PharmaCyte Biotech Inc (PMCB)

[bulldurham]

( NVLX ) Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers

In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.

the only thing this little mice study needs to prove is slowing the accumulation of ascites fluid in cancer patients ....

this is what will get Nuvilex noticed...

bull